A Look At BridgeBio Pharma (BBIO) Valuation After Mixed Short Term Returns And Strong Long Term Gains

Simply Wall St.

Apr 26

BridgeBio Pharma (BBIO) is in focus after recent trading left the stock with a one-month return of about 2% and a decline of roughly 6% over the past three months. That mixed pattern prompts closer ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.gotigerhk.com/news/2630809234"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2630809234\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2630809234?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","is_english":true,"pubTime":"2026-04-26 01:07","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2630809234","market":"us","top_or_hot":-1,"title":"A Look At BridgeBio Pharma (BBIO) Valuation After Mixed Short Term Returns And Strong Long Term Gains","media":"Simply Wall St.","content":"<div>\n<p>BridgeBio Pharma (BBIO) is in focus after recent trading left the stock with a one-month return of about 2% and a decline of roughly 6% over the past three months. That mixed pattern prompts closer ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-bbio/bridgebio-pharma/news/a-look-at-bridgebio-pharma-bbio-valuation-after-mixed-short\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>A Look At BridgeBio Pharma (BBIO) Valuation After Mixed Short Term Returns And Strong Long Term Gains</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nA Look At BridgeBio Pharma (BBIO) Valuation After Mixed Short Term Returns And Strong Long Term Gains\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-04-26 01:07 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-bbio/bridgebio-pharma/news/a-look-at-bridgebio-pharma-bbio-valuation-after-mixed-short><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>BridgeBio Pharma (BBIO) is in focus after recent trading left the stock with a one-month return of about 2% and a decline of roughly 6% over the past three months. That mixed pattern prompts closer ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-bbio/bridgebio-pharma/news/a-look-at-bridgebio-pharma-bbio-valuation-after-mixed-short\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-bbio/bridgebio-pharma/news/a-look-at-bridgebio-pharma-bbio-valuation-after-mixed-short","article_id":"2630809234","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-bbio/bridgebio-pharma/news/a-look-at-bridgebio-pharma-bbio-valuation-after-mixed-short","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2630809234","pubTimestamp":1777136864,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"BridgeBio Pharma (BBIO) is in focus after recent trading left the stock with a one-month return of about 2% and a decline of roughly 6% over the past three months. That mixed pattern prompts closer attention.\nSee our latest analysis for BridgeBio Pharma.\nThe recent 2.25% 1 day share price return and 2.33% 30 day share price return sit against a weaker year to date share price return of 6.33%. At the same time, the 1 year total shareholder return of about 102% and the very large 3 year total...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","BK4585":"ETF&股票定投概念","BK4588":"碎股","BBIO":"BridgeBio Pharma, Inc.","BK4505":"高瓴资本持仓"},"translate_title":"在短期回报参差不齐和长期强劲收益后审视BridgeBio Pharma(BBIO)的估值","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BBIO":1.5},"content_text":"BridgeBio Pharma (BBIO) is in focus after recent trading left the stock with a one-month return of about 2% and a decline of roughly 6% over the past three months. That mixed pattern prompts closer attention. See our latest analysis for BridgeBio Pharma. The recent 2.25% 1 day share price return and 2.33% 30 day share price return sit against a weaker year to date share price return of 6.33%. At the same time, the 1 year total shareholder return of about 102% and the very large 3 year total shareholder return of around 4x highlight that longer term momentum remains strong even as shorter term sentiment looks more cautious. If BridgeBio Pharma has caught your eye, it can be useful to see what else is moving in related areas, including companies in healthcare using artificial intelligence, via the 33 healthcare AI stocks With revenue of US$502.1m, a reported net loss of US$724.9m and a recent share price of US$73.28, the key question is whether BridgeBio Pharma still trades at a discount or if the market is already pricing in future growth. AdvertisementMost Popular Narrative: 27.2% Undervalued Against the last close at $73.28, the most followed fair value estimate of $100.61 suggests a sizeable gap that hinges on future earnings power and margins.  The company's late-stage pipeline, with three Phase III readouts imminent across high unmet need rare disease indications, positions BridgeBio to leverage advancements in biotechnology for potential first-to-market and best-in-class therapies. This creates the opportunity for multiple revenue inflection points and margin improvement as the portfolio diversifies. Established commercial and patient support infrastructure, enabled by strong sales execution and white-glove access models, is expected to be redeployed for future launches. This could reduce incremental fixed costs per new product and support long-term operational leverage and net margin expansion.  Read the complete narrative. Curious what earnings, revenue growth, and margin profile need to line up to support that kind of uplift? The underlying narrative leans on ambitious compounding and a future profit multiple usually associated with established sector leaders. Result: Fair Value of $100.61 (UNDERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, this relies heavily on Attruby and a handful of late stage trials. As a result, any clinical setbacks or slower uptake could quickly challenge that upbeat narrative. Find out about the key risks to this BridgeBio Pharma narrative. Another View: High Sales Multiple Flags Valuation Tension The analyst narrative uses a fair value estimate of $100.61 based on future earnings and margins, while the stock currently trades on a P/S of 28.3x. That is higher than both the US Biotechs industry at 11.4x and peers at 14.7x, and also above a fair ratio of 19.6x. In plain terms, the current price already reflects a substantial amount of anticipated success, which raises the question of how comfortable investors are with that gap between the narrative and the current price. See what the numbers say about this price — find out in our valuation breakdown. NasdaqGS:BBIO P/S Ratio as at Apr 2026Next Steps The mix of optimism and caution around BridgeBio Pharma is clear, so it makes sense to move quickly, review the data yourself, and weigh both sides. To see the full picture of potential upside and downside in one place, take a look at the 2 key rewards and 1 important warning sign Looking for more investment ideas? If BridgeBio Pharma is on your radar, do not stop there. Using targeted stock lists can reveal opportunities you would otherwise miss.  Target income potential by reviewing companies offering resilient payouts in the 13 dividend fortresses Spot quality at a discount by scanning companies that appear attractively priced in the 56 high quality undervalued stocks Prioritise capital preservation by focusing on companies screened for resilience in the 72 resilient stocks with low risk scores   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.Valuation is complex, but we're here to simplify it.Discover if BridgeBio Pharma might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}